Sign in
Taking peoplePhase 3

Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm

Key facts

Who runs it
Versailles Hospital
Where
France29 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
674 people, planned
Started
6 Nov 2025
Expected to end
15 Mar 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Amiodarone
Record updated
23 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patient aged ≥ 18 years
  • Admitted in intensive care unit
  • Out-of-hospital cardiac arrest with initial shockable rhythm
  • Presumed cardiac or unknown cause
  • Delay between ROSC and screening for randomisation < 6 hours
  • Informed consent from the patient or a surrogate or deferred consent
  • Affiliated to or benefiting from a social insurance

Who cannot take part

  • Known limitations in therapy and Do Not Resuscitate-order
  • Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)
  • Thyroid disease under treatment
  • History of cardiac conduction disorders, not treated by permanent pacemaker
  • Refractory ventricular arrhythmia or electrical storm
  • Patient with known interstitial lung disease
  • Patient needing a nadolol treatment due to QT long syndrome or catecholaminergic polymorphic ventricular tachycardia
  • Indication for amiodarone decided by the physician at ICU admission
  • No central venous catheter available for continuous infusion of amidoarone
  • Any contra indication to amiodarone treatment
  • Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission
  • Moribund patient due to pre-arrest history (estimated life expectancy < 3 months)
  • Pregnant or breastfeeding women
  • Patient with known pulmonary fibrosis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)

The 2 groups in the trial

  • AmiodaroneTreatment being tested

    Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.

  • ControlNo study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm.
Record updated
23 December 2025